Our top pick for
Long-term investors
Dicerna Pharmaceuticals Inc is a biotechnology business based in the US. Dicerna Pharmaceuticals shares (DRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Dicerna Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Dicerna Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – DRNA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Dicerna Pharmaceuticals stock price (NASDAQ: DRNA)
Use our graph to track the performance of DRNA stocks over time.Dicerna Pharmaceuticals shares at a glance
Information last updated 2022-01-24.
| Latest market close | $38.22 |
|---|---|
| 52-week range | $19.06 - $40.14 |
| 50-day moving average | $31.45 |
| 200-day moving average | $28.97 |
| Wall St. target price | $38.25 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.63 |
Buy Dicerna Pharmaceuticals shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Dicerna Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Dicerna Pharmaceuticals price performance over time
Historical closes compared with the close of $38.22 from 2021-12-29
| 1 week (2022-01-14) | N/A |
|---|---|
| 1 month (2021-12-23) | 0.58% |
| 3 months (2021-10-25) | 79.02% |
| 6 months (2021-07-23) | 1.89% |
| 1 year (2021-01-25) | 48.14% |
|---|---|
| 2 years (2020-01-24) | 98.44% |
| 3 years (2019-01-25) | 276.55% |
| 5 years (2017-01-25) | 1,284.78% |
Dicerna Pharmaceuticals financials
| Revenue TTM | $192.9 million |
|---|---|
| Gross profit TTM | $-41,077,000 |
| Return on assets TTM | -10.43% |
| Return on equity TTM | -95.22% |
| Profit margin | -64.53% |
| Book value | $1.38 |
| Market capitalisation | $3 billion |
TTM: trailing 12 months
Dicerna Pharmaceuticals share dividends
We're not expecting Dicerna Pharmaceuticals to pay a dividend over the next 12 months.
Dicerna Pharmaceuticals share price volatility
Over the last 12 months, Dicerna Pharmaceuticals's shares have ranged in value from as little as $19.06 up to $40.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dicerna Pharmaceuticals's is 0.786. This would suggest that Dicerna Pharmaceuticals's shares are less volatile than average (for this exchange).
Dicerna Pharmaceuticals overview
Dicerna Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Dicerna Pharmaceuticals in the news
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Dicerna Pharmaceuticals : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - Form 8-K
DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
Frequently asked questions
What percentage of Dicerna Pharmaceuticals is owned by insiders or institutions?Currently 7.434% of Dicerna Pharmaceuticals shares are held by insiders and 88.539% by institutions. How many people work for Dicerna Pharmaceuticals?
Latest data suggests 302 work at Dicerna Pharmaceuticals. When does the fiscal year end for Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals's fiscal year ends in December. Where is Dicerna Pharmaceuticals based?
Dicerna Pharmaceuticals's address is: 75 Hayden Avenue, Lexington, MA, United States, 02421 What is Dicerna Pharmaceuticals's ISIN number?
Dicerna Pharmaceuticals's international securities identification number is: US2530311081 What is Dicerna Pharmaceuticals's CUSIP number?
Dicerna Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 253031108
More guides on Finder
-
Walmart dives deep into the metaverse with crypto and NFTs
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
-
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
-
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
-
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
-
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
-
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
-
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
-
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Ask an Expert